---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002728"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:58:37.982479+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical appoints Benjamin Yerxa, Ph.D. to Board of Directors

## Summary
- Dr. Yerxa, CEO of Foundation Fighting Blindness and Clearside co-founder, appointed effective March 2, 2022.
- Received option to purchase 30,000 shares at $1.49/share, vesting in 36 monthly installments.
- Entitled to $40,000 annual retainer plus annual option grants for service as director.
- His expertise expected to advance CLS-AX (axitinib) for wet AMD and SCS platform.

## SEC filing metadata
- accession: 0000950170-22-002728
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/0000950170-22-002728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/clsd-20220303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002728
- JSON: https://secwatch.observer/filing/0000950170-22-002728.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002728.txt

## Key facts
- Executive change
  Benjamin Yerxa was appointed as director at Clearside Biomedical, Inc..
  - Action: appointed
  - Role: director
  source text: the board of directors (the “ Board ”) of Clearside Biomedical, Inc. (the “ Company ”) appointed Benjamin Yerxa to serve as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017022002728/0000950170-22-002728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.